Cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, has demonstrated promising antitumor efficacy across multiple solid tumors, including cervical cancer, gastric cancer, hepatocellular carcinoma, and non-small cell lung cancer. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.